您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Aldometanib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Aldometanib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Aldometanib图片
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议
200mg电议
500mg电议

产品名称
LXY-05-029
产品介绍
Aldometanib (LXY-05-029) 是一种醛缩酶抑制剂。Aldometanib 可以激活溶酶体腺苷-磷酸活化蛋白激酶AMPK并降低血糖。Aldometanib 可用于代谢稳态的研究。
生物活性

Aldometanib (LXY-05-029) is an orally activealdolaseinhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis[1].

体外研究
(In Vitro)

Aldometanib (0-1000 nM; 2 h) activates AMPK by preventing aldolase from binding to FBP to engender a pseudo-starvation signal[1].

Western Blot Analysis[1]

Cell Line:Mouse primary hepatocytes, MEFs cells
Concentration:0-1000 nM
Incubation Time:2 h
Result:Activated AMPK in mouse embryonic fibroblasts (MEFs) and mouse primary hepatocytes cells.

Immunofluorescence[1]

Cell Line:MEFs cells
Concentration:5 nM
Incubation Time:2 h
Result:Inhibited TRPVs and induces AXIN lysosomal translocation.
体内研究
(In Vivo)

Aldometanib (oral; 0-10 mpk) reduces blood glucose in lean mice[1].
Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice[1].
Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis[1].
Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice[1].
Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan inC. elegansvia the lysosomal pathway[1].

Animal Model:Lean mice[1]
Dosage:0-10 mpk
Administration:Oral
Result:Decreased fasting blood glucose and improved glucose tolerance, promoted muscular TBC1D1 phosphorylation and glucose uptake.
Animal Model:Obese hyperglycaemic mice[1]
Dosage:2-10 mpk
Administration:Oral, twice daily, for a week
Result:Decreased blood glucose, lowered blood glucose in a muscular AMPK-dependent manner reduced hepatic TAG, improved insulin sensitivity, increased glucose disposal rates, inhibited TAG synthesis in liver and primary hepatocytes, decreased fat mass.
Animal Model:NASH mice[1]
Dosage:2 mpk
Administration:Oral, twice-daily, for a month
Result:Decreased histological scores used to describe the features of NASH, reduced apoptosis rate of hepatic cells, inhibited inflammatory responses in the liver of NASH mice and improved glucose tolerance of NASH mice.
Animal Model:C. elegans[1]
Dosage:0-50 μM
Administration:Oral, 0-50 days
Result:Promoted oxidative stress resistance and mitochondrial functions inC. elegans.
Animal Model:C57BL/6 mice[1]
Dosage:100 μg/mL
Administration:Oral
Result:Extended lifespan, elevated NADlevels and mitochondrial oxidative respiration, rejuvenated muscle function in aged mice.
分子量

593.45

性状

Solid

Formula

C27H43Cl2IN2

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

溶解性数据
In Vitro: 

DMSO : 100 mg/mL(168.51 mM;ultrasonic and warming and heat to 60℃)

配制储备液
浓度溶剂体积质量1 mg5 mg10 mg
1 mM1.6851 mL8.4253 mL16.8506 mL
5 mM0.3370 mL1.6851 mL3.3701 mL
10 mM0.1685 mL0.8425 mL1.6851 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。